Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dAMD-1
- Development stage
- Preclinical
- Lead developer
- insitro
01
Overview
dAMD-1 is a preclinical drug candidate being developed by **insitro** for the treatment of dry age-related macular degeneration (dAMD). Discovered using insitro's proprietary machine learning-driven platform, the asset was identified by integrating high-content cellular data with human genetics to model disease states in vitro, specifically utilizing iPSC-derived retinal pigment epithelium (RPE) cells. The program aims to address the underlying biological drivers of geographic atrophy and vision loss associated with dAMD. As of early 2024, specific details regarding the molecular target, therapeutic modality, and route of administration remain proprietary and have not been publicly disclosed.
- Other names
- dAMD-1-insitro-dAMDdAMD1-insitro-dAMDdAMD 1-insitro-dAMD
Beyond the preview
Go deeper on dAMD-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dAMD-1.